Accessing TSB Regenerative Technology Millions Seminar
End : 10 Mar 2010 - 14:00
The Technology Strategy Board is to invest a further £6m in regenerative medicine research and development and has invited British companies to bid for funding through two new competitions.
As part of a £21.5m programme in regenerative medicine, the Board is to invest up to £4m in commercial research and development projects in regenerative medicine therapeutics. A second competition will see investment of up to £2m in feasibility projects in regenerative medicine tools and technologies. Both competitions open on 8 March 2010.
The aim of the Developing Therapeutics competition is to enable UK businesses to carry out preclinical and clinical development of regenerative medicine therapeutic products. The competition will enable consortia to accelerate product development to take advantage of future market or funding opportunities.
Meanwhile, the aim of the Tools and Technologies Feasibility Studies competition is to enable UK businesses to address challenges currently being faced by developers of regenerative medicine therapeutics through the development of platform technologies. Particular challenges to be addressed through the competition include the ability to assess the safety and/or efficacy of therapeutic products and being able to develop reproducible and robust manufacturing processes.
Agenda
10.30 - 10.45 Registration and Refreshments
10.45 - 11.00 Introduction to SEHTA, Dr David Parry, CEO
11.00 - 12.20 Accessing TSB Regenerative Technology Millions, Dr Zahid Latif
Lead Technologist in Medicines and Healthcare, TSB
12.00 - 14.00 Lunch and 1:1 meetings
14.00 Close
If you would like a 1:1 meeting with Dr Latif to discuss proposals, please contact Claire Ansett
Venue: Leatherhead Food Research, Leatherhead, Surrey
This event is free of charge, but please note that this event is only open to SEHTA Members. Please click here to register as member.
To register for this event please email your name, job title, company name, telephone and email details to

